Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Zipprich

Showing results (41-50 of 111) with videos related to

Pageof 12
Sort By:
Zeitschrift Fur Gastroenterologie|February 3, 2023
[Successful therapy of non-cirrhotic non-malignant portal vein thrombosis (NCNMPT) by interventional therapy using transjugular lysis catheter]Frank David Dannecker, Rene Aschenbach, Ulf Teichgräber, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 29, 2024
Exploring the Relationship Between NOD2 Risk Variants and First Decompensation Events in Cirrhotic Patients With VaricesHenrik Karbannek, Matthias C Reichert, Robin Greinert, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 12, 2012
Prognostic indicators of survival in patients with compensated and decompensated cirrhosisAlexander Zipprich, Guadalupe Garcia-Tsao, Sebastian Rogowski, et al.
Hepatology (Baltimore, Md.)|January 24, 2003
Functional significance of hepatic arterial flow reserve in patients with cirrhosisAlexander Zipprich, Norbert Steudel, Curd Behrmann, et al.
Hepatology Communications|October 12, 2022
Evaluation of the definition of hyperdynamic circulation in patients with cirrhosis and ascitesCristina Ripoll, Luis Ibáñez-Samaniego, Beatrix Neumann, et al.
Zeitschrift Fur Gastroenterologie|May 28, 2026
[Therapy-refractory hepatic encephalopathy or acquired hepato-cerebral degeneration - a challenging differential diagnosis]Vanessa Trentzsch, Marija Stojiljković, Philipp A Reuken, et al.
Hepatology Communications|September 24, 2021
Protective Effects of Statin Therapy in Cirrhosis Are Limited by a Common SLCO1B1 Transporter VariantMelissa Merkel, Christina Schneider, Robin Greinert, et al.
Cytotherapy|October 28, 2017
Improvement of portal venous pressure in cirrhotic rat livers by systemic treatment with adipose tissue-derived mesenchymal stromal cellsSandra Brückner, Alexander Zipprich, Madlen Hempel, et al.
British Journal of Pharmacology|April 24, 2018
The selective mineralocorticoid receptor antagonist eplerenone prevents decompensation of the liver in cirrhosisBarbara Schreier, Anja Wolf, Stefanie Hammer, et al.
Cell Communication and Signaling : CCS|December 20, 2024
Eplerenone, a mineralocorticoid receptor inhibitor, reduces cirrhosis associated changes of hepatocyte glucose and lipid metabolismMohammad Mohabbulla Mohib, Sindy Rabe, Alexander Nolze, et al.
Pageof 12

Showing results (41-50 of 111) with videos related to

Sort By:
Pageof 12
Zeitschrift Fur Gastroenterologie|February 3, 2023
[Successful therapy of non-cirrhotic non-malignant portal vein thrombosis (NCNMPT) by interventional therapy using transjugular lysis catheter]Frank David Dannecker, Rene Aschenbach, Ulf Teichgräber, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 29, 2024
Exploring the Relationship Between NOD2 Risk Variants and First Decompensation Events in Cirrhotic Patients With VaricesHenrik Karbannek, Matthias C Reichert, Robin Greinert, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 12, 2012
Prognostic indicators of survival in patients with compensated and decompensated cirrhosisAlexander Zipprich, Guadalupe Garcia-Tsao, Sebastian Rogowski, et al.
Hepatology (Baltimore, Md.)|January 24, 2003
Functional significance of hepatic arterial flow reserve in patients with cirrhosisAlexander Zipprich, Norbert Steudel, Curd Behrmann, et al.
Hepatology Communications|October 12, 2022
Evaluation of the definition of hyperdynamic circulation in patients with cirrhosis and ascitesCristina Ripoll, Luis Ibáñez-Samaniego, Beatrix Neumann, et al.
Zeitschrift Fur Gastroenterologie|May 28, 2026
[Therapy-refractory hepatic encephalopathy or acquired hepato-cerebral degeneration - a challenging differential diagnosis]Vanessa Trentzsch, Marija Stojiljković, Philipp A Reuken, et al.
Hepatology Communications|September 24, 2021
Protective Effects of Statin Therapy in Cirrhosis Are Limited by a Common SLCO1B1 Transporter VariantMelissa Merkel, Christina Schneider, Robin Greinert, et al.
Cytotherapy|October 28, 2017
Improvement of portal venous pressure in cirrhotic rat livers by systemic treatment with adipose tissue-derived mesenchymal stromal cellsSandra Brückner, Alexander Zipprich, Madlen Hempel, et al.
British Journal of Pharmacology|April 24, 2018
The selective mineralocorticoid receptor antagonist eplerenone prevents decompensation of the liver in cirrhosisBarbara Schreier, Anja Wolf, Stefanie Hammer, et al.
Cell Communication and Signaling : CCS|December 20, 2024
Eplerenone, a mineralocorticoid receptor inhibitor, reduces cirrhosis associated changes of hepatocyte glucose and lipid metabolismMohammad Mohabbulla Mohib, Sindy Rabe, Alexander Nolze, et al.
Pageof 12